Pharma Reviews: Glenmark's debt reduction, IPO for life sciences arm may trigger re-rating

The company has seen about 105% growth during the quarter, as per Indian Pharma Market data. Hence, one may expect strong domestic sales ...
Read more: Glenmark's debt reduction, IPO for life sciences arm may trigger re-rating